In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care.
The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike.
Guest: Prof Josep-María Ribera
Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe